Withdrawal of cerivastatin from the world market
<p>Abstract</p> <p>Cerivastatin was recently withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure. The risk was found to be higher among patients who received the full dose (0.8 mg/day) and those who received gemfibroz...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2001-09-01
|
| Series: | Current Controlled Trials in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | http://cvm.controlled-trials.com/content/2/5/205 |